EKF Diagnostics, Cardiff, UK, has signed a 3-year agreement with Tosoh Europe, Amsterdam, the Netherlands, to distribute its Quo-Test glycated hemoglobin (HbA1c) point-of-care (POC) analyzer in the Middle East and Africa. The desktop analyzer will complement Tosoh’s line of high-performance liquid chromatography (HPLC) equipment for HbA1c analysis predominantly in core laboratories.
Julian Baines, EKF Diagnostics.
“We are delighted to partner with Tosoh Europe as they expand their need for point-of-care HbA1c analysis in a time where those suffering from diabetes are at greater risk,” says Julian Baines, chief executive officer of EKF. “Tosoh is a leading HPLC brand and its analyzers are considered to be the gold standard when validating POC products such as EKF’s Quo-Test. For them to choose our analyzer to complement their lab-based HPLC analyzers for HbA1c testing is a great endorsement of our technology.”
Quo-Test is fully automated and quantifies HbA1c from a 4 μL sample taken from a fingerstick or venous whole blood. Unaffected by most hemoglobin variants, lab-quality results are available within 4 minutes. Step-by-step instructions are shown on Quo-Test’s multilingual display, minimizing staff training time and user-related errors.
For more information, visit EKF Diagnostics and Tosoh Europe.
